PDCD1 and neoplasm: Consequently, immune checkpoint inhibition, which inhibits an interaction of PD-1 and PD-L1, and thus enables reactivation of the adaptive immune response, can lead to a competent response of the immune system against the tumor cells and contribute to an improved response to treatment (Mukherji et al. 2022).